Wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

PC HF part 2

Total questions: 21

Worksheet time: 11mins

Name
Class
Date
1.

How does a NEP inhibitor lower BP?

a)

increases the level of vasodilator peptides

b)

decreases the level of vasoactive peptides

c)

decreases level elf vasoconstrictor peptides

d)

increases the level of vasoconstrictor peptides

2.

Which of the following inhibitors increases the level of vasoactive peptides?

a)

renin inhibitors

b)

PDE inhibitors

c)

NEP inhibitors

d)

ACE inhibitors

3.

NEP causes

a)

vasodilation in all vessels

b)

vasoconstriction in all vessels

c)

effect largely depends on whether the predominant substrate degraded by NEP is a vasodilator or vasoconstrictor

4.

In vasoconstriction, NEP is involved in the enzymatic conversion of Big ET-1 to its active form. What is the active form?

a)

ET-1

b)

BNP

c)

ANP

d)

ANG-11

5.

Which of the following reduces the risk of CV death and HF hospitalization?

a)

sacubitril/valsartan

b)

sildenafil

c)

lithium

d)

spironolactone

6.

The film coated tablet of Entresto are unstable in which pH?

a)

alkaline

b)

neutral

c)

acidic

d)

none of the above

7.

Which of the following is FALSE regarding Entresto?

a)

no starting dose adjustment is needed for mild or moderate renal impairment

b)

can be taken with or without food

c)

not recommended in severe renal impairment

d)

does not cross the BBB

8.

If a patient has severe renal impairment and is starting Entresto, what must be done?

a)

starting dose adjustment is necessary

b)

no starting dose adjustment is required

c)

not recommended in severe renal impairment

d)

recommend a different drug

9.

Sacubitril is a prodrug that is activated to Sacubitrilat (LBQ657) by __________ via _________.

a)

demethylation; esterases

b)

de-ethylation; esterases

c)

hydrolysis; amidase

d)

decarboxylation; hydrolysis

10.

What are the 2 mechanisms of action for Entresto (Sacubitril/Valsartan)?

a)

inhibits angiotensin converting enzyme

b)

inhibits Na/K ATPase

c)

inhibits neprilysin

d)

blocks the AT1 receptor

11.

Although the clinical relevance is unknown, which drug increases the levels of amyloid-B1 in the cerebrospinal fluid?

a)

Entresto

b)

Ivabradine

c)

omaprartilat

d)

carvedilol

12.

Sacubitril/Valsartan (Entresto) may result in what adverse event(s)?

a)

angoiedema

b)

hypotension

c)

impaired renal function

d)

all of these

13.

Which drug(s) should NOT be taken with Entresto?

a)

ACEIs

b)

NSAIDs

c)

COX-2 Inhibitors

d)

all of these

14.

Which of the following drugs interacts with spironolactone?

a)

sodium supplement

b)

potassium supplement

c)

magnesium supplements

15.

Next generation ARBs will inhibit _________ using bifunctional single compounds that reduces the adverse effects associated with combination therapy.

a)

neprilysin activity

b)

AT1 receptor response

c)

AT2 receptor response

d)

the renin-angiotensin system

16.

Ivabradine inhibits...

a)

hyperpolarization-activated cyclic nucleotide gated (HCN) channels

b)

NEP

c)

renin

d)

angiotensin II

17.

Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker that does what to the spontaneous pacemaker activity of the cardiac sinus node?

a)

increases

b)

nothing

c)

reduces

18.

Which of the following is an adverse reaction of Ivabradine?

a)

conduction disturbances

b)

luminous phenomena (phosphenes)

c)

suicidal ideation

d)

tachycardia

19.

Which of the following is true regarding Ivabradine?

a)

use can cause ventricular fibrillation

b)

safe to use while breastfeeding

c)

ivabradine is safe in pregnancy

d)

use can cause heart block

20.

Which of the following is NOT an adverse reaction of ivabradine?

a)

fetal toxicity

b)

atrial fibrillation

c)

hepatotoxicity

d)

bradycardia

21.

All are adverse reactions to Entresto, except:

a)

angioedema

b)

hypoglycemia

c)

hypotension

d)

hyperkalemia